{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:13:57Z","timestamp":1787973237638,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Department of Science and Technology of Gansu Province","award":["21JR1RA119"],"award-info":[{"award-number":["21JR1RA119"]}]},{"name":"Basic research of science and technology innovation application - surface project","award":["CY2021-MS-B03"],"award-info":[{"award-number":["CY2021-MS-B03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04567-2","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T15:16:06Z","timestamp":1747235766000},"page":"3993-4001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)\u2014based on real-world data analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Shaolong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyun","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"2","key":"4567_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3322\/caac.21713","volume":"72","author":"J Ferlay","year":"2022","unstructured":"Ferlay J, Colombet M, Soerjomataram I et al (2022) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 72(2):121\u2013148. https:\/\/doi.org\/10.3322\/caac.21713","journal-title":"CA Cancer J Clin"},{"key":"4567_CR2","unstructured":"World Health Organization (2021) International agency for research on cancer. GLOBOCAN 2020: cancer incidence and mortality worldwide. https:\/\/gco.iarc.fr\/"},{"key":"4567_CR3","unstructured":"National Comprehensive Cancer Network (2021) NCCN guidelines: bladder cancer. https:\/\/www.nccn.org\/guidelines\/guidelines-list"},{"issue":"3","key":"4567_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19(3):666\u2013675. https:\/\/doi.org\/10.1200\/JCO.2001.19.3.666","journal-title":"J Clin Oncol"},{"issue":"6","key":"4567_CR5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone NJ, Shipley WU, Clayman RH et al (2017) Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience. Eur Urol 71(6):952\u2013960. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.020","journal-title":"Eur Urol"},{"issue":"11","key":"4567_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"issue":"1","key":"4567_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2035807","volume":"385","author":"JE Rosenberg","year":"2021","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV et al (2021) Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-PD-1 therapy. N Engl J Med 385(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2035807","journal-title":"N Engl J Med"},{"issue":"7","key":"4567_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22(7):931\u2013945. https:\/\/doi.org\/10.1016\/S1470-2045(21)00152-2","journal-title":"Lancet Oncol"},{"issue":"7693","key":"4567_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548. https:\/\/doi.org\/10.1038\/nature25501","journal-title":"Nature"},{"issue":"2","key":"4567_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.023","volume":"77","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, de Mulder PHM, Schornagel JH et al (2020) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors. Eur Urol 77(2):223\u2013231. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.023","journal-title":"Eur Urol"},{"issue":"3","key":"4567_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.04.030","volume":"70","author":"SP Lerner","year":"2016","unstructured":"Lerner SP, Dinney C, Kamat A et al (2016) Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Eur Urol 70(3):447\u2013454. https:\/\/doi.org\/10.1016\/j.eururo.2016.04.030","journal-title":"Eur Urol"},{"issue":"8","key":"4567_CR12","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1001\/jamaoncol.2019.0891","volume":"5","author":"GS Kulkarni","year":"2019","unstructured":"Kulkarni GS, Hermanns T, Wei Y et al (2019) Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. JAMA Oncol 5(8):1154\u20131161. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0891","journal-title":"JAMA Oncol"},{"issue":"3","key":"4567_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O'Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16(3):151\u2013167. https:\/\/doi.org\/10.1038\/s41571-018-0142-8","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"4567_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1056\/NEJMoa2206533","volume":"387","author":"DF Bajorin","year":"2022","unstructured":"Bajorin DF, Witjes JA, Gschwend JE et al (2022) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 387(12):1057\u20131067. https:\/\/doi.org\/10.1056\/NEJMoa2206533","journal-title":"N Engl J Med"},{"issue":"21","key":"4567_CR15","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21):4602\u20134608. https:\/\/doi.org\/10.1200\/JCO.2005.07.757","journal-title":"J Clin Oncol"},{"issue":"17","key":"4567_CR16","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J et al (2011) Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy. J Clin Oncol 29(17):2432\u20132438. https:\/\/doi.org\/10.1200\/JCO.2011.34.8433","journal-title":"J Clin Oncol"},{"issue":"3","key":"4567_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/SPC.0000000000000148","volume":"9","author":"JK Rudzinski","year":"2015","unstructured":"Rudzinski JK, Basappa NS, North S (2015) Perioperative chemotherapy for muscle invasive bladder cancer. Curr Opin Support Palliat Care 9(3):249\u2013254. https:\/\/doi.org\/10.1097\/SPC.0000000000000148","journal-title":"Curr Opin Support Palliat Care"},{"issue":"3","key":"4567_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102085","volume":"22","author":"A Wang","year":"2024","unstructured":"Wang A, Chen M, Li D et al (2024) Disitamab vedotin alone or in combination with immune checkpoint inhibitors in bladder-sparing treatment of muscle-invasive bladder cancer: a real-world study. Clin Genitourin Cancer 22(3):102085. https:\/\/doi.org\/10.1016\/j.clgc.2024.102085","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"4567_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng X, Yan X, Wang L et al (2021) Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res 27(1):43\u201351","journal-title":"Clin Cancer Res"},{"key":"4567_CR20","doi-asserted-by":"publisher","unstructured":"Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19(10):2638\u20132646. https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2638","DOI":"10.1200\/JCO.2001.19.10.2638"},{"key":"4567_CR21","doi-asserted-by":"publisher","unstructured":"Alqahtani MM (2024) Cisplatin-induced renal failure measured by glomerular filtration rate (GFR) with\u00a099mTc-DTPA scans in cancer patients: a systematic review and meta-analysis.\u00a0Diagnostics 14(22):2468. https:\/\/doi.org\/10.3390\/diagnostics14222468","DOI":"10.3390\/diagnostics14222468"},{"issue":"11","key":"4567_CR22","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I et al (2024) The hallmarks of cancer immune evasion. Cancer Cell 42(11):1825\u20131863. https:\/\/doi.org\/10.1016\/j.ccell.2024.09.010","journal-title":"Cancer Cell"},{"key":"4567_CR23","doi-asserted-by":"crossref","unstructured":"Zlotta AR, Ballas LK, Niemierko A et al (2022) Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer. J Clin Oncol 40(suppl 6; abstr 433)","DOI":"10.1200\/JCO.2022.40.6_suppl.433"},{"issue":"10","key":"4567_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"issue":"1","key":"4567_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-015-3503-3","volume":"153","author":"X Yao","year":"2015","unstructured":"Yao X, Jiang J, Wang X et al (2015) A novel humanized antiHER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat 153(1):123\u2013133","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"4567_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A et al (2012) Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12(12):860\u2013875","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"4567_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6(6):865\u2013871. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"},{"issue":"23","key":"4567_CR28","doi-asserted-by":"publisher","first-page":"21159","DOI":"10.1002\/cam4.6680","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu J, Zhang H, Zhang L et al (2023) Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: a multicenter, retrospective clinical study. Cancer Med 12(23):21159\u201321171. https:\/\/doi.org\/10.1002\/cam4.6680","journal-title":"Cancer Med"},{"issue":"9","key":"4567_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"4567_CR30","doi-asserted-by":"publisher","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update [published correction appears. J Clin Oncol 40(3):315. https:\/\/doi.org\/10.1200\/JCO.21.02786; J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","DOI":"10.1200\/JCO.21.02786"},{"key":"4567_CR31","doi-asserted-by":"publisher","unstructured":"Shatila M, Zhang HC, Shirwaikar Thomas A et al (2024) Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. J Immunother Cancer 12(11):e009742. https:\/\/doi.org\/10.1136\/jitc-2024-009742","DOI":"10.1136\/jitc-2024-009742"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04567-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04567-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04567-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:08:28Z","timestamp":1761847708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04567-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4567"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04567-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Patient consent was waived due to this study is a retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}